RA Capital Management 13F holdings, Q3 2017
Holdings as of September 30, 2017 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 27 US equity positions worth $1.1bn in its Q3 2017 13F filing. The largest position was ASND at 18.3% of the reported book, followed by WVE and AVEXIS INC. Against the Q2 2017 filing, it opened 9 new positions, added to 4 and reduced 3 among the top 27 holdings.
What did RA Capital Management own in Q3 2017? Top 27 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q2 2017 |
|---|---|---|---|---|---|---|---|
| 1 | ASND ASCENDIS PHARMA A S | Healthcare | 18.3% | $202.3m | 5,580,690 | 0% | held |
| 2 | WVE WAVE LIFE SCIENCES LTD | Healthcare | 13.9% | $154.2m | 7,088,651 | 0% | held |
| 3 | AVEXIS INC | 10.8% | $119.8m | 1,238,181 | -5% | reduced | |
| 4 | BIOHAVEN PHARMACTL HLDG CO LTD | 6.7% | $74.7m | 1,997,278 | -18% | reduced | |
| 5 | ACHILLION PHARMACEUTICALS INC | 5.5% | $61.2m | 13,633,220 | 0% | held | |
| 6 | IGNYTA INC | 4.6% | $50.7m | 4,106,601 | 2% | added | |
| 7 | G1 THERAPEUTICS INC | 4.5% | $49.8m | 2,684,244 | 0% | held | |
| 8 | KALA PHARMACEUTICALS INC | 4.4% | $48.3m | 2,113,236 | – | new | |
| 9 | MYOVANT SCIENCES LTD | 4.0% | $43.8m | 2,830,455 | 1% | added | |
| 10 | AVEO PHARMACEUTICALS INC | 3.7% | $41.4m | 11,328,646 | 34% | added | |
| 11 | BCRX BIOCRYST PHARMACEUTICALS | Healthcare | 3.3% | $36.6m | 6,984,692 | 35% | added |
| 12 | ZOGENIX INC | 3.1% | $34.8m | 992,268 | -33% | reduced | |
| 13 | INSM INSMED INC | Healthcare | 2.0% | $22.6m | 722,714 | – | new |
| 14 | KDMN KADMON HLDGS INC | 2.0% | $22.3m | 6,666,666 | – | new | |
| 15 | ACORDA THERAPEUTICS INC | 1.9% | $21.3m | 900,259 | 0% | held | |
| 16 | IMMU IMMUNOMEDICS INC | 1.9% | $20.7m | 1,478,742 | – | new | |
| 17 | RA PHARMACEUTICALS INC | 1.8% | $19.7m | 1,351,808 | 0% | held | |
| 18 | SGMOQ SANGAMO THERAPEUTICS INC | Healthcare | 1.7% | $18.8m | 1,250,000 | 0% | held |
| 19 | DICERNA PHARMACEUTICALS INC | 1.3% | $14.0m | 2,428,571 | 0% | held | |
| 20 | AQUINOX PHARMACEUTICALS INC | 0.9% | $10.1m | 710,682 | – | new | |
| 21 | CLEMENTIA PHARMACEUTICALS INC COM NPV | 0.9% | $9.9m | 585,403 | – | new | |
| 22 | TGTX TG THERAPEUTICS INC | Healthcare | 0.7% | $8.3m | 700,000 | 0% | held |
| 23 | KRYS KRYSTAL BIOTECH INC | Healthcare | 0.6% | $7.0m | 700,000 | – | new |
| 24 | VNDA VANDA PHARMACEUTICALS INC | Healthcare | 0.4% | $4.4m | 243,971 | – | new |
| 25 | 4XC1 KALVISTA PHARMACEUTICALS INC | 0.4% | $4.3m | 591,070 | 0% | held | |
| 26 | CHIASMA INC | 0.3% | $3.6m | 1,396,400 | – | new | |
| 27 | PROTEON THERAPEUTICS INC | 0.2% | $2.7m | 1,337,462 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.